Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection. Capone, G. L., Putignano, A. L., Trujillo Saavedra, S., Paganini, I., Sestini, R., Gensini, F., De Rienzo, I., Papi, L., & Porfirio, B. The Journal of Molecular Diagnostics, 20(1):87–94, January, 2018. ![Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex 2 downloads The efficiency of a novel targeted next-generation sequencing (NGS) test, the Devyser BRCA kit, for a comprehensive analysis of all 48 coding exons of the high-risk breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 has been assessed. The new assay intended to detect nucleotide substitutions, small deletions/insertions, and large deletions/duplications. To document the false-negative and false-positive rates of the NGS assay in the hands of end users, 48 samples with previously identified 444 small variants and seven gross rearrangements were analyzed, showing 100% concordance with gold standards. Furthermore, all other 43 variants (42 single-nucleotide variation or insertion/deletion variation and one copy number variation, whose significance is or may be of clinical value), which were called by the NGS assay in a prospectively analyzed 179-sample set, were confirmed by Sanger sequencing or multiplex ligation probe amplification, according to their nature. We conclude that the Devyser BRCA kit performed satisfactorily for use in a clinical laboratory.
@article{capone_evaluation_2018,
title = {Evaluation of a {Next}-{Generation} {Sequencing} {Assay} for {BRCA1} and {BRCA2} {Mutation} {Detection}},
volume = {20},
issn = {1525-1578},
url = {http://www.sciencedirect.com/science/article/pii/S1525157817303380},
doi = {10.1016/j.jmoldx.2017.09.005},
abstract = {The efficiency of a novel targeted next-generation sequencing (NGS) test, the Devyser BRCA kit, for a comprehensive analysis of all 48 coding exons of the high-risk breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 has been assessed. The new assay intended to detect nucleotide substitutions, small deletions/insertions, and large deletions/duplications. To document the false-negative and false-positive rates of the NGS assay in the hands of end users, 48 samples with previously identified 444 small variants and seven gross rearrangements were analyzed, showing 100\% concordance with gold standards. Furthermore, all other 43 variants (42 single-nucleotide variation or insertion/deletion variation and one copy number variation, whose significance is or may be of clinical value), which were called by the NGS assay in a prospectively analyzed 179-sample set, were confirmed by Sanger sequencing or multiplex ligation probe amplification, according to their nature. We conclude that the Devyser BRCA kit performed satisfactorily for use in a clinical laboratory.},
language = {en},
number = {1},
urldate = {2020-02-11},
journal = {The Journal of Molecular Diagnostics},
author = {Capone, Gabriele Lorenzo and Putignano, Anna Laura and Trujillo Saavedra, Sharon and Paganini, Irene and Sestini, Roberta and Gensini, Francesca and De Rienzo, Irene and Papi, Laura and Porfirio, Berardino},
month = jan,
year = {2018},
keywords = {BRCA1, BRCA1/2, BRCA2, Benchmark, Blood, Breast cancer, Bundle, CNV, Genomics, HBOC, Hereditary Disorders, INDEL, Illumina Sequencer, Liquid Biopsy, Oncology, Ovarian Cancer, SNV, SOPHiA DDM, Solid Tumor, Targeted},
pages = {87--94},
}
Downloads: 2
{"_id":"jbmFTi24cuWMDt9mr","bibbaseid":"capone-putignano-trujillosaavedra-paganini-sestini-gensini-derienzo-papi-etal-evaluationofanextgenerationsequencingassayforbrca1andbrca2mutationdetection-2018","author_short":["Capone, G. L.","Putignano, A. L.","Trujillo Saavedra, S.","Paganini, I.","Sestini, R.","Gensini, F.","De Rienzo, I.","Papi, L.","Porfirio, B."],"bibdata":{"bibtype":"article","type":"article","title":"Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection","volume":"20","issn":"1525-1578","url":"http://www.sciencedirect.com/science/article/pii/S1525157817303380","doi":"10.1016/j.jmoldx.2017.09.005","abstract":"The efficiency of a novel targeted next-generation sequencing (NGS) test, the Devyser BRCA kit, for a comprehensive analysis of all 48 coding exons of the high-risk breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 has been assessed. The new assay intended to detect nucleotide substitutions, small deletions/insertions, and large deletions/duplications. To document the false-negative and false-positive rates of the NGS assay in the hands of end users, 48 samples with previously identified 444 small variants and seven gross rearrangements were analyzed, showing 100% concordance with gold standards. Furthermore, all other 43 variants (42 single-nucleotide variation or insertion/deletion variation and one copy number variation, whose significance is or may be of clinical value), which were called by the NGS assay in a prospectively analyzed 179-sample set, were confirmed by Sanger sequencing or multiplex ligation probe amplification, according to their nature. We conclude that the Devyser BRCA kit performed satisfactorily for use in a clinical laboratory.","language":"en","number":"1","urldate":"2020-02-11","journal":"The Journal of Molecular Diagnostics","author":[{"propositions":[],"lastnames":["Capone"],"firstnames":["Gabriele","Lorenzo"],"suffixes":[]},{"propositions":[],"lastnames":["Putignano"],"firstnames":["Anna","Laura"],"suffixes":[]},{"propositions":[],"lastnames":["Trujillo","Saavedra"],"firstnames":["Sharon"],"suffixes":[]},{"propositions":[],"lastnames":["Paganini"],"firstnames":["Irene"],"suffixes":[]},{"propositions":[],"lastnames":["Sestini"],"firstnames":["Roberta"],"suffixes":[]},{"propositions":[],"lastnames":["Gensini"],"firstnames":["Francesca"],"suffixes":[]},{"propositions":[],"lastnames":["De","Rienzo"],"firstnames":["Irene"],"suffixes":[]},{"propositions":[],"lastnames":["Papi"],"firstnames":["Laura"],"suffixes":[]},{"propositions":[],"lastnames":["Porfirio"],"firstnames":["Berardino"],"suffixes":[]}],"month":"January","year":"2018","keywords":"BRCA1, BRCA1/2, BRCA2, Benchmark, Blood, Breast cancer, Bundle, CNV, Genomics, HBOC, Hereditary Disorders, INDEL, Illumina Sequencer, Liquid Biopsy, Oncology, Ovarian Cancer, SNV, SOPHiA DDM, Solid Tumor, Targeted","pages":"87–94","bibtex":"@article{capone_evaluation_2018,\n\ttitle = {Evaluation of a {Next}-{Generation} {Sequencing} {Assay} for {BRCA1} and {BRCA2} {Mutation} {Detection}},\n\tvolume = {20},\n\tissn = {1525-1578},\n\turl = {http://www.sciencedirect.com/science/article/pii/S1525157817303380},\n\tdoi = {10.1016/j.jmoldx.2017.09.005},\n\tabstract = {The efficiency of a novel targeted next-generation sequencing (NGS) test, the Devyser BRCA kit, for a comprehensive analysis of all 48 coding exons of the high-risk breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 has been assessed. The new assay intended to detect nucleotide substitutions, small deletions/insertions, and large deletions/duplications. To document the false-negative and false-positive rates of the NGS assay in the hands of end users, 48 samples with previously identified 444 small variants and seven gross rearrangements were analyzed, showing 100\\% concordance with gold standards. Furthermore, all other 43 variants (42 single-nucleotide variation or insertion/deletion variation and one copy number variation, whose significance is or may be of clinical value), which were called by the NGS assay in a prospectively analyzed 179-sample set, were confirmed by Sanger sequencing or multiplex ligation probe amplification, according to their nature. We conclude that the Devyser BRCA kit performed satisfactorily for use in a clinical laboratory.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-02-11},\n\tjournal = {The Journal of Molecular Diagnostics},\n\tauthor = {Capone, Gabriele Lorenzo and Putignano, Anna Laura and Trujillo Saavedra, Sharon and Paganini, Irene and Sestini, Roberta and Gensini, Francesca and De Rienzo, Irene and Papi, Laura and Porfirio, Berardino},\n\tmonth = jan,\n\tyear = {2018},\n\tkeywords = {BRCA1, BRCA1/2, BRCA2, Benchmark, Blood, Breast cancer, Bundle, CNV, Genomics, HBOC, Hereditary Disorders, INDEL, Illumina Sequencer, Liquid Biopsy, Oncology, Ovarian Cancer, SNV, SOPHiA DDM, Solid Tumor, Targeted},\n\tpages = {87--94},\n}\n\n","author_short":["Capone, G. L.","Putignano, A. L.","Trujillo Saavedra, S.","Paganini, I.","Sestini, R.","Gensini, F.","De Rienzo, I.","Papi, L.","Porfirio, B."],"key":"capone_evaluation_2018","id":"capone_evaluation_2018","bibbaseid":"capone-putignano-trujillosaavedra-paganini-sestini-gensini-derienzo-papi-etal-evaluationofanextgenerationsequencingassayforbrca1andbrca2mutationdetection-2018","role":"author","urls":{"Paper":"http://www.sciencedirect.com/science/article/pii/S1525157817303380"},"keyword":["BRCA1","BRCA1/2","BRCA2","Benchmark","Blood","Breast cancer","Bundle","CNV","Genomics","HBOC","Hereditary Disorders","INDEL","Illumina Sequencer","Liquid Biopsy","Oncology","Ovarian Cancer","SNV","SOPHiA DDM","Solid Tumor","Targeted"],"metadata":{"authorlinks":{}},"downloads":2},"bibtype":"article","biburl":"https://bibbase.org/zotero/SOPHiAGENETICS","dataSources":["Pcpsxmwz8uxXtL843","vPYMrJTaJTbhFPPb4"],"keywords":["brca1","brca1/2","brca2","benchmark","blood","breast cancer","bundle","cnv","genomics","hboc","hereditary disorders","indel","illumina sequencer","liquid biopsy","oncology","ovarian cancer","snv","sophia ddm","solid tumor","targeted"],"search_terms":["evaluation","next","generation","sequencing","assay","brca1","brca2","mutation","detection","capone","putignano","trujillo saavedra","paganini","sestini","gensini","de rienzo","papi","porfirio"],"title":"Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection","year":2018,"downloads":2}